

# Newcastle 85+ Study

<https://neurodegenerationresearch.eu/survey/newcastle-85-study/>

## Title of the cohort

Newcastle 85+ Study

## Acronym for cohort

Newcastle 85+ Study

## Name of Principal Investigator

Title Professor

First name Thomas

Last name Kirkwood

## Address of institution where award is held

Institution Newcastle University Institute for Ageing and Health

Street Address Campus for Ageing and Vitality

City Newcastle upon Tyne

Postcode NE4 5PL

## Country

United Kingdom

## Website

[www.ncl.ac.uk/iah](http://www.ncl.ac.uk/iah)

## Contact email

[tom.kirkwood@ncl.ac.uk](mailto:tom.kirkwood@ncl.ac.uk)

## Funding source

Medical research council

## 1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias
- Parkinson's disease
- Neurodegenerative disease in general

## When studies on the above condition(s) are expected to become possible

Already possible

## 2a. Stated aim of the cohort

To investigate in great detail the clinical, biological and psychosocial factors associated with ageing among a fully representative cohort all born in 1921 and aged 85 at entry.

## **2b. Features distinguishing this cohort from other population cohorts**

High recruitment rate (72%) from target population including those living in institutions and with cognitive impairment. Very extensive multi-dimensional health assessment including a wide range of functional tests and assessments, blood-based biomarkers, activity monitoring and questionnaires, as well as review of GP records.

### **3a. i) Number of publications that involve use of cohort to date**

6

### **3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**

Kirkwood, Newcastle University Institute for Ageing and Health, Health and disease in 85 year olds  
Adamson, Newcastle University Institute of Health and Society, Dietary assessment in the Newcastle 85+ study

Jagger, Newcastle University Institute for Ageing and Health, Projections of future care needs

### **3b. Publication list/link to where data or publications are accessible (if available)**

Collerton J, Barrass K, Bond J, Eccles M, Jagger C, James OFW, Martin-Ruiz C, Robinson AL, von Zglinicki T, Kirkwood TBL. The Newcastle 85+ study: biological clinical and psychosocial factors associated with healthy ageing: study protocol. BMC Geriatrics. 2007;7:14.

Collerton J, Collerton D, Arai Y, Barrass K, Eccles M, Jagger C, McKeith IG, Saxby BK, Kirkwood TBL. A comparison of the acceptability, feasibility and utility of computerised and pencil and paper tasks in assessing cognitive function in community dwelling older people in the Newcastle 85+ Pilot Study. Journal American Geriatric Psychiatry 2007;55:1630-1635.

Collerton JC, Martin-Ruiz C, Kenny A, Barrass K, Von Zglinicki T, Kirkwood TBL, et al. Telomere length is associated with left ventricular function in the oldest old: the Newcastle 85+ study. European Heart Journal 2007;28:172-176.

Adamson AJ, Collerton J, Davies K, Foster E, Jagger C, Stamp E, Mathers JC, Kirkwood TBL; Newcastle 85+ Study Core Team. Nutrition in advanced age: dietary assessment in the Newcastle 85+ study. Eur J Clin Nutr. 2009;63:S6-18.

Collerton J, Davies K, Jagger C, Kingston A, Bond J, Eccles MP, Robinson LA, Martin-Ruiz C, von Zglinicki T, James OF, Kirkwood TBL. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ. 2009;339:b4904.

Jagger C, Collerton JC, Davies K, Kingston A, Robinson LA, Eccles MP, von Zglinicki T, Martin-Ruiz C, James OF, Kirkwood TBL, Bond J. Capability and dependency in the Newcastle 85+ cohort study. Projections of future care needs. BMC Geriatrics 2011;11:21.

### **3c. Information (i.e. research findings) expected to be gained from the population cohort**

#### **4a. Study criteria: age range of participants at recruitment**

Age in years from: 85

To ('until death' if applicable): 86

**4b. Study criteria: inclusion criteria**

Resident in Newcastle or North Tyneside and registered there with a GP.

Born in 1921

**4c. Study criteria: exclusion criteria**

None other than exclusion by GP as being in last stages of terminal illness or as posing a potential safety risk to a visiting member of the research team.

**5. Size of the cohort (i.e. number of participants enrolled)**

1,000 – 5,000 participants

**6a. Measures used to characterise participants**

**6b. Additional measures for participants with a clinical disorder**

No

**6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

No

**7. Study design**

- Prospective cohort

**8. Cases matched by**

- Age

**9a. Does the study include a specialised subset of control participants**

No

**9b. If yes, description of specialised subset of control participants**

**10a. i) Data collection start date**

01-06-2006

**10a. ii) Data collection end date**

31-03-2011

**10a iii) Data collection for this study is**

- Data collection ongoing
- Data analysis ongoing
- Closed to new patients

#### **10b. Plans to continue the cohort study beyond the current projected end date**

- Yes – funding applied for

#### **11. Data collected**

- Only through the study

#### **12. System in place to enable re-contact with patients for future studies**

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

#### **13a. Format and availability of data stored in a database**

Yes/No % available

Data summarised in database Yes 85%

Database is web-based

Database on spreadsheet Yes 85%

Database is on paper

Other (specify)

#### **Language used:**

#### **13b. Format and availability of data held as individual records**

Yes/No % available

Data held as individual records

Data is web-based

Data held on computer based records Yes 85%

Data held on cards

Other (specify)

#### **Language used:**

#### **14a. Are data available to other groups**

Yes

#### **14b. Access policy/mechanisms for access if data are available to other groups**

- Apply to PI or co-ordinator at resource
- Access Committee mechanism

#### **15. Data sharing policy specified as a condition of use**

No requirement to make data publicly available

#### **16a. Are tissues/samples/DNA available to other groups**

Yes

**16b. i) Description of available tissues/samples/DNA**

- Living donors: blood derivatives
- Living donors: DNA

**16b. ii) Form available tissues/samples/DNA are supplied in**

- Secondary samples: plasma
- Secondary samples: DNA

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

Yes

**17. Is information on biological characteristics available to other groups**

- Yes, for all the cohort